6 withdrawn. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 6 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP) - Graft Versus Host Disease | Phase 2 | Withdrawn | Molly Gallogly | 2024-10-01 | 2025-01-07 | |
| Tocilizumab for Chronic Graft-versus-Host Disease Treatment tocilizumab, laboratory biomarker analysis, quality-of-life assessment - Graft Versus Host Disease | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-02-01 | 2016-05-06 | |
| Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease brentuximab vedotin, laboratory biomarker analysis, pharmacological study - Graft Versus Host Disease | Phase 2 | Withdrawn | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2012-09-01 | 2013-06-27 | |
| Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant cyclosporine, methotrexate, sirolimus - Graft Versus Host Disease, Leukemia | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 1996-03-01 | 2015-03-06 | |
| OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide - Graft Versus Host Disease, Leukemia | Phase 2 | Withdrawn | Mesoblast International Sàrl | 2014-12-04 | ||
| Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia therapeutic allogeneic lymphocytes, cytarabine, fludarabine phosphate - Graft Versus Host Disease, Leukemia | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2020-07-31 |
Graft vs Host Disease (6) · Leukemia (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myeloid, Chronic-Phase (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Congenital Abnormalities (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Immune System Diseases (6) · Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2)
Methotrexate (3) · Cyclosporine (2) · Peripheral Blood Stem Cell Transplantation (2) · Brentuximab Vedotin (1) · Busulfan (1) · Cyclophosphamide (1) · Cytarabine (1) · Disulfides (1) · Idarubicin (1) · Immunoglobulin G (1) · Photopheresis (1) · Radiotherapy (1) · Sirolimus (1) · Tacrolimus (1) · fludarabine phosphate (1)
Fred Hutchinson Cancer Center (2) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Jonsson Comprehensive Cancer Center (1) · Mesoblast International Sàrl (1) · Molly Gallogly (1)
United States (4)
Gary J. Schiller, MD (1) · H. Joachim Deeg, MD (1) · Mary C. Territo, MD (1) · Merav Bar (1) · Molly Gallogly, MD, PhD (1) · Stephanie Lee (1)
P30CA015704 (1)